PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 30, issue 12, 2012

Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis pp. 1101-1117

Marta O. Soares and Luísa Canto e Castro

Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis pp. 1101-1117

Marta Soares and Luísa Canto e Castro

Bevacizumab for Metastatic Colorectal Cancer pp. 1119-1132

Sophie Whyte, Abdullah Pandor and Matt Stevenson

Bevacizumab for Metastatic Colorectal Cancer pp. 1119-1132

Sophie Whyte, Abdullah Pandor and Matt Stevenson

A Systematic Review and Critical Assessment of Health State Utilities pp. 1133-1143

Scott Doyle, Andrew Lloyd, Lee Moore, Joshua Ray and Alastair Gray

A Systematic Review and Critical Assessment of Health State Utilities pp. 1133-1143

Scott Doyle, Andrew Lloyd, Lee Moore, Joshua Ray and Alastair Gray

Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis pp. 1145-1156

Cécile Gaujoux-Viala and Bruno Fautrel

Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis pp. 1145-1156

Cécile Gaujoux-Viala and Bruno Fautrel

Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis pp. 1157-1171

Lanting Lu, Hilary Pearce, Chris Roome, James Shearer, Iain A. Lang and Ken Stein

Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis pp. 1157-1171

Lanting Lu, Hilary Pearce, Chris Roome, James Shearer, Iain Lang and Ken Stein

Chemotherapy Administration pp. 1173-1186

Philip Haywood, Johan Raad, Kees Gool, Marion Haas, Gisselle Gallego, Sallie-Anne Pearson, Margaret Faedo and Robyn Ward

Chemotherapy Administration pp. 1173-1186

Philip Haywood, Johan Raad, Kees Gool, Marion Haas, Gisselle Gallego, Sallie-Anne Pearson, Margaret Faedo and Robyn Ward

What’s Good and Bad About Contraceptive Products? pp. 1187-1202

Stephanie A. Knox, Rosalie Viney, Deborah J. Street, Marion R. Haas, Denzil Fiebig, Edith Weisberg and Deborah Bateson

What’s Good and Bad About Contraceptive Products? pp. 1187-1202

Stephanie Knox, Rosalie Viney, Deborah Street, Marion Haas, Denzil Fiebig, Edith Weisberg and Deborah Bateson

Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets pp. 1203-1214

Liv Ariane Augestad, Kim Rand-Hendriksen, Ivar Sønbø Kristiansen and Knut Stavem

Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets pp. 1203-1214

Liv Augestad, Kim Rand-Hendriksen, Ivar Kristiansen and Knut Stavem

Volume 30, issue 11, 2012

Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis pp. 981-989

Daniel Grima, Lisa Bernard, Elizabeth Dunn, Philip McFarlane and David Mendelssohn

Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years pp. 991-1004

Jane Burch, Susan Griffin, Claire McKenna, Simon Walker, James Paton, Kath Wright and Nerys Woolacott

The Burden of Moderate to Severe Psoriasis pp. 1005-1013

Giovanna Raho, Daniela Mihajlova Koleva, Livio Garattini and Luigi Naldi

Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups pp. 1015-1034

Ava John-Baptiste, Man Yeung, Victoria Leung, Gabrielle Velde and Murray Krahn

Losing Sight of the Wood for the Trees pp. 1035-1049

Paul Dolan, Henry Lee and Tessa Peasgood

A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand pp. 1051-1065

Rajan Ragupathy, Katri Aaltonen, June Tordoff, Pauline Norris and David Reith

The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes pp. 1067-1084

Laura Panattoni, Paul Brown, Braden Ao, Mark Webster and Patrick Gladding

The General Public’s Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimer’s Disease Medication pp. 1085-1095

Mark Oremus, Jean-Eric Tarride, Parminder Raina, Lehana Thabane, Gary Foster, Charlie Goldsmith and Natasha Clayton

Volume 30, issue 10, 2012

Private Manufacturers’ Thresholds to Invest in Comparative Effectiveness Trials pp. 859-868

Anirban Basu and David Meltzer

New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses pp. 869-885

Douglas Mapel and Melissa Roberts

Counting the Cost of Not Costing HIV Health Facilities Accurately pp. 887-902

Eduard Beck, Carlos Avila, Sofia Gerbase, Guy Harling and Paul Lay

The Cost Effectiveness of Newer Epilepsy Treatments pp. 903-923

Kristian Bolin and Lars Forsgren

The State of Health Economic Research in South Africa pp. 925-940

Paul Gavaza, Karen Rascati, Abiola Oladapo and Star Khoza

Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting pp. 941-959

Laura McCullagh, Cathal Walsh and Michael Barry

Patient Preferences for Community Pharmacy Asthma Services pp. 961-976

Pradnya Naik-Panvelkar, Carol Armour, John Rose and Bandana Saini

The Authors’ Reply pp. 977-978

Mark Bounthavong, Christine Nguyen, Margaret Mendes, Melissa Christopher, Josephine Tran, Rashid Kazerooni and Anthony Morreale

Validity of Cost and Utility Results? pp. 977-977

Alex Diamantopoulos, Laura Sawyer, Sarika Ogale and Fred Dejonckheere

Is There a Role for Pharmacoeconomics in Decision Making? pp. 979-979

Johan Luijn

The Authors’ Reply pp. 980-980

Ties Hoomans, Johan Severens, Nicole Roer and Gepke Delwel

Volume 30, issue 9, 2012

Assessing the Quality of Pharmacoeconomic Studies in India pp. 749-762

Pooja Desai, Hitesh Chandwani and Karen Rascati

Cost of Illness of Cystic Fibrosis in Germany pp. 763-777

Mareike Heimeshoff, Helge Hollmeyer, Jonas Schreyögg, Oliver Tiemann and Doris Staab

Reimbursement Decisions of the All Wales Medicines Strategy Group pp. 779-794

Warren Linley and Dyfrig Hughes

Lost Productivity in Four European Countries among Patients with Rheumatic Disorders pp. 795-807

Saskia Knies, Math Candel, Annelies Boonen, Silvia Evers, Andre Ament and Johan Severens

Costs Associated with Febrile Neutropenia in the US pp. 809-823

Shannon Michels, Rich Barron, Matthew Reynolds, Karen Tomic, Jingbo Yu and Gary Lyman

A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease pp. 825-840

Petra Menn, Reiner Leidl and Rolf Holle

Dabigatran Etexilate pp. 841-855

Kate McKeage

Caregivers’ Quality of Life and Economic Evaluations pp. 857-858

Afschin Gandjour

The Authors’ Reply pp. 858-858

Hareth Al-Janabi, Terry Flynn and Joanna Coast

Volume 30, issue 8, 2012

Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents pp. e1-e15

Vanja Sikirica, M. Erder, Jipan Xie, Dendy Macaulay, Melissa Diener, Paul Hodgkins and Eric Wu

Valuing Children’s Health pp. 633-635

Eve Wittenberg

Comparative Effectiveness and Child Health pp. 637-645

Lisa Prosser

Economic Evaluations of Childhood Influenza Vaccination pp. 647-660

Anthony Newall, Mark Jit and Philippe Beutels

Preference-Based Health-Related Quality-of-Life Outcomes in Children with Autism Spectrum Disorders pp. 661-679

J. Tilford, Nalin Payakachat, Erica Kovacs, Jeffrey Pyne, Werner Brouwer, Todd Nick, Jayne Bellando and Karen Kuhlthau

The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt pp. 681-695

Mark Connolly, Oleksandr Topachevskyi, Baudouin Standaert, Omayra Ortega and Maarten Postma

A Parent-Child Dyad Approach to the Assessment of Health Status and Health-Related Quality of Life in Children with Asthma pp. 697-712

Wendy Ungar, Katherine Boydell, Sharon Dell, Brian Feldman, Deborah Marshall, Andrew Willan and James Wright

Developing Adolescent-Specific Health State Values for Economic Evaluation pp. 713-727

Julie Ratcliffe, Terry Flynn, Frances Terlich, Katherine Stevens, John Brazier and Michael Sawyer

Valuation of the Child Health Utility 9D Index pp. 729-747

Katherine Stevens

Volume 30, issue 7, 2012

Cost Effectiveness of Rituximab for Non-Hodgkin’s Lymphoma pp. 537-549

Philipp Auweiler, Dirk Müller, Stephanie Stock and Andreas Gerber

Economic Evaluation of Smoking-Cessation Therapies pp. 551-564

Kristian Bolin

Hospital Reimbursement Price Cap for Cancer Drugs pp. 565-573

Albane Degrassat-Théas, M. Bensadon, C. Rieu, M. Angalakuditi, C. Pen and P. Paubel

Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis pp. 575-593

Christine Nguyen, Mark Bounthavong, Margaret Mendes, Melissa Christopher, Josephine Tran, Rashid Kazerooni and Anthony Morreale

Duloxetine Use in Chronic Low Back Pain pp. 595-609

Jasmina Ivanova, Howard Birnbaum, Evan Kantor, Matt Schiller and Ralph Swindle

Quetiapine pp. 611-631

Greg Plosker

Volume 30, issue 6, 2012

Value of Information and Pricing New Healthcare Interventions pp. 447-459

Andrew Willan and Simon Eckermann

A Critical Review of Model-Based Economic Studies of Depression pp. 461-482

Hossein Ali Afzali, Jonathan Karnon and Jodi Gray

Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura pp. 483-495

Dwayne Boyers, Xueli Jia, David Jenkinson and Graham Mowatt

Pharmacoeconomics of the Myeloid Growth Factors pp. 497-511

Bradford Hirsch and Gary Lyman

Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode pp. 513-530

Mattias Ekman, Peter Lindgren, Carolin Miltenburger, Genevieve Meier, Julie Locklear and Mary Chatterton

The Lack of Impact of Quality-of-Life Measures in Schizophrenia: A Shared Responsibility? pp. 531-532

Laurent Boyer and Pascal Auquier

The Authors’ Reply pp. 532-533

A. Awad and Lakshmi Voruganti

Erratum to Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study pp. 534-535

Laura Pizzi, Amy Talati, Eric Gemmen, Naomi Dahl, Thomas Bunz and Peter Sand

Volume 30, issue 4, 2012

Golimumab for the Treatment of Psoriatic Arthritis pp. 257-270

Huiqin Yang, Dawn Craig, David Epstein, Laura Bojke, Kate Light, Ian Bruce, Mark Sculpher and Nerys Woolacott

Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease pp. 271-302

Maureen Rutten- van Mölken and Lucas Goossens

Cost Effectiveness of Anticoagulation in Acute Coronary Syndromes pp. 303-321

Jaime Latour-Pérez and Eva -Miguel-Balsa

Changes in Utilization and Costs for Patients with Rheumatoid Arthritis, 1997 to 2006 pp. 323-336

Howard Birnbaum, Crystal Pike, Ritesh Banerjee, Tracy Waldman and Mary Cifaldi

Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program pp. 337-353

Nadia Demarteau, Thomas Breuer and Baudouin Standaert

Volume 30, issue 3, 2012

Population–versus Cohort–Based Modelling Approaches pp. 171-181

Olivier Ethgen and Baudouin Standaert

Measuring Quality of Life in Patients with Schizophrenia pp. 183-195

A. Awad and Lakshmi Voruganti

Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7 pp. 197-211

Frank Lichtenberg

Pricing Human Papillomavirus Vaccines pp. 213-217

Livio Garattini, Katelijne Vooren and Alessandro Curto

Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands pp. 219-227

Ties Hoomans, Johan Severens, Nicole Roer and Gepke Delwel

Common Drug Review Recommendations pp. 229-246

Angela Rocchi, Elizabeth Miller, Robert Hopkins and Ron Goeree

Rufinamide pp. 247-256

Paul McCormack

Volume 30, issue 2, 2012

Health Utility Elicitation pp. 83-86

Lisa Prosser, Scott Grosse and Eve Wittenberg

Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective pp. 87-101

Aurea Duran, Nishan Sengupta, Alexander Diamantopoulos, Fiona Forster, Louis Kwong and Michael Lees

Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer pp. 103-118

Robert Griffiths, Richard Barron, Michelle Gleeson, Mark Danese, Anthony O’Hagan, Victoria Chia, Jason Legg and Gary Lyman

Incorporating Calibrated Model Parameters into Sensitivity Analyses pp. 119-126

Douglas Taylor, Vivek Pawar, Denise Kruzikas, Kristen Gilmore, Myrlene Sanon and Milton Weinstein

Why Not Real Economics? pp. 127-131

F. Reed Johnson

Real Economics Needs to Reflect Real Decisions pp. 133-136

Mark Sculpher and Karl Claxton

Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery pp. 137-146

Michael Holmes, Christopher Carroll and Diana Papaioannou

Osteoporotic Fractures pp. 147-170

Sangeeta Budhia, Yeshi Mikyas, Michael Tang and Enkhe Badamgarav

Volume 30, issue 1, 2012

Economic and Humanistic Burden of External Genital Warts pp. 1-16

Adam Raymakers, Mohsen Sadatsafavi, Fawziah Marra and Carlo Marra

Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer pp. 17-34

Mathilda Bongers, Veerle Coupé, Elise Jansma, Egbert Smit and Carin Groot

Dronedarone for the Treatment of Atrial Fibrillation pp. 35-46

Claire McKenna, Emma Maund, Muhammad Sarowar, David Fox, Matt Stevenson, Chris Pepper, Nerys Woolacott and Stephen Palmer

Does the EQ-5D Reflect Lost Earnings? pp. 47-61

Carl Tilling, Marieke Kro, Aki Tsuchiya, John Brazier, Job van Exel and Werner Brouwer

A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis pp. 63-80

Christopher Fitzpatrick and Katherine Floyd

Erratum to Systematic Reviewof the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis pp. 81-81

C. Fitzpatrick and K. Floyd